Medinol hired Harvey J. Berger, MD, as executive chairman of the company’s operations in the U.S.
Medinol, a cardiovascular device manufacturer with headquarters in Tel Aviv, Israel, announced the hiring on Feb. 16.
Berger was the founder and former chairman and CEO of Ariad Pharmaceuticals, which develops and commercializes medications for patients with rare cancers. Takeda completed the acquisition of Ariad on Feb. 16 for $24 per share in cash, or approximately $5.2 billion.
At Medinol US, Berger, 66, will work with the company’s core business of interventional cardiovascular devices and help it develop sub-millimeter implantable sensors, unique percutaneous aortic valves and other complementary products.
Before founding Ariad in 1991, Berger worked as an executive at Centocor, which is now known as Janssen Biotech. After graduating from the Yale School of Medicine, Berger was a tenured professor at Yale, Emory University and the University of Pennsylvania.
“I am honored to join Medinol as Executive Chairman of Medinol US Inc. and work closely with Judith and Kobi Richter, the founders of Medinol, and its highly committed and capable employees in Israel and the U.S.,” Berger said in a news release. “Judith and Kobi have offered me an extraordinary opportunity to help them and other company leaders grow Medinol into the preeminent medical device and technology company they should be. The extensive intellectual-property portfolio and novel technologies under development at Medinol extend far beyond its initial focus on novel coronary artery stents. I anticipate that these will contribute directly to Medinol’s continued innovation, future products and commercial success as an industry leader.”